Remember. Jurassic park failed because every other thing was built while sparing no expenses and only one programmer was underpaid.

Don't underpay programmers.

I previously worked as a Linux/unix sysadmin. There was one app team owning like 4 servers accessible in a very speciffic way.
* logon to main jumpbox
* ssh to elevated-privileges jumpbox
* logon to regional jumpbox using custom-made ssh alternative [call it fkup]
* try to fkup to the app server to confirm that fkup daemon is dead
* logon to server's mgmt node [aix frame]
* ssh to server directly to find confirm sshd is dead too
* access server's console
* place root pswd request in passwords vault, chase 2 mangers via phone for approvals [to login to the vault, find my request and aprove it]
* use root pw to login to server's console, bounce sshd and fkupd
* logout from the console
* fkup into the server to get shell.

That's not the worst part... Aix'es are stable enough to run for years w/o needing any maintenance, do all this complexity could be bearable.

However, the app team used to log a change request asking to copy a new pdf file into that server every week and drop it to app directory, chown it to app user. Why can't they do that themselves you ask? Bcuz they 'only need this pdf to get there, that's all, and we're not wasting our time to raise access requests and chase for approvals just for a pdf...'

oh, and all these steps must be repeated each time a sysadmin tties to implement the change request as all the movements and decisions must be logged and justified.

Each server access takes roughly half an hour. 4 servers -> 2hrs.

So yeah.. Surely getting your accesses sorted out once is so much more time consuming and less efficient than logging a change request for sysadmins every week and wasting 2 frickin hours of my time to just copy a simple pdf for you.. Not to mention that threr's only a small team of sysadmins maintaining tens of thousands of servers and every minute we have we spend working. Lunch time takes 10-15 minutes or so.. Almost no time for coffee or restroom. And these guys are saying sparing a few hours to get their own accesses is 'a waste of their time'...

That was the time I discovered skrillex.

It took literally days to get our software installed onto the client VMs and get the services started correctly.

On our own test VMs the same task takes all of about an hour or so. Mind you these VMs are supposed to be created and match the client's environment almost too the T. Same configurations, same third party software, same environment variables and the whole 9 yards.

This was not the case at all.

Environment variables were not set, third party software was not installed, and I honestly don't remember the list of things wrong with how they setup the VM. Sparing the details, the errors were also not helpful.

They also gave us critical information we needed for development days before we were going on site to test. The amount of hackery we had to do could be a completely separate rant on its own.

While desperately trying to to stay sane long enough to get our services started, the only thing I could think was how great it would be if there was a fire or something. Anything, just to have an excuse to go back to the hotel and actually sleep. The second day there we finally had everything installed and running.

I shit you not, just as we began our first test, the fire alarms went off.

At this point in time the team was extremely (pissed tf off) annoyed to put it mildly. Assuming it was just a drill, we left our stuff and went to eat dinner. After we came back we found out it in fact was not a drill...

Moral of the story:
Don't wish bad fortune on a customer even if out of impulsive spite.

Other moral of the story:
Don't leave your belongings behind only because you think the fire alarms are just a fire drill. It may not be.

P.S. Karma's a bitch.

from rant import workflow

Tl;dr - I have a share of the product's backend, everyone expects it to work, no one cares how and i can spare with i, me, and myself getting there.

CTO: We need this solution, what do you need for data?
ME: Okay, thing0, thing1, thing2, preferably a ton of samples.
C: Here, also, there's a new full-timer who will help you. And you can do some sparing with.
M: Cool, i have several approaches to discuss.
*new full-timer attends fewer times than me as a part-timer*
*standup meetings talks about status, problems - yeah, whatever reactions*
*full-timer doesn't attend still, gets a "quick" (in case of consistently showing up) task to fix something in another backend part*
Me @ a standup lately: So, approach 4 worked, polishing it, but I soon-ish need to know a few things so I can finish up and fully integrate it.
CTO: Okay, when *full-timer* gets in so she's included.
*waiting for X days (x>8)*

Do anyone use spring framework ? I thought it is popular among developers

I've been an android/anti-ios person for around a decade and im now seriously considering switching to ios when the new iphones land. My mother is an apple nut and my brother is on android and everytime i bring up even the slightest nitpick about ios or macos (such as the fact that the "always use this application" checkbox on macos does not work or that you have to upload music through itunes) they jump on the "wtf then why would even consider it??????" train. In short its because ios seems at least a little bit more stable overall (havent had much experience with ios in general this is really more of a first impression). Well I got a replacement LG V20 just over a year ago and it has not aged well, had to replace the battery because i barely got 4 hours with minimal usage, even when i got the thing it was rather jittery, and its just now getting oreo (and surely wont be getting pie). Hell i was removing several apps earlier and it took a solid 4 MINUTES to uninstall an icon pack. After some investigation into the ios ecosystem i found that all the apps that i would need are on there so that was great. What im really hoping for though is some stability/longevity, im ok with paying around 1000 for a phone if it lasts a while and stays in decent shape. Finally the fact that the updates are sparing at best (with the exception of pixel phones) is a great annoyance whereas my mothers (around 4 years old) ipad is rocking ios 11. Could someone who has made the leap make a recommendation? I love android but i feel like all i would accomplish is buying another phone that craps out after less than a year.

Cancer Immunotherapy Market Extensive Industry Analysis, Growth Rate, Segmentation, Investment Opportunities and Top Manufacturers 2035

The global cancer immunotherapy market is on a promising trajectory, with a projected value increase from USD 134.40 billion in 2024 to USD 346.63 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.8%. This innovative therapeutic approach leverages the body’s immune system to identify and combat cancer cells, presenting a compelling alternative to traditional treatments like chemotherapy and radiation, which often come with significant side effects.

Market Growth Projections

The market is anticipated to grow significantly, reaching USD 148.73 billion in 2025 before hitting USD 346.63 billion by 2035. The rising incidence of cancer globally, projected to see around 2,041,910 new cases and approximately 618,120 deaths in the U.S. alone by 2025, is a primary driver behind this growth.

Drivers of Growth

Key factors propelling the market include the increasing prevalence of cancer and a growing demand for targeted therapies. Cancer immunotherapy offers a more precise approach, effectively directing the immune response to target cancerous cells while sparing normal cells. This specificity has made it a preferred treatment modality, especially for patients who have developed resistance to traditional therapies.

Segmentation

The cancer immunotherapy market is segmented by several criteria:

1. Type of Product: This includes immune checkpoint inhibitors, cell therapies, cancer vaccines, immunomodulators, monoclonal antibodies, and oncolytic viral therapies.
2. Application: Key applications include breast cancer, colorectal cancer, head and neck cancer, lung cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, and others.
3. Route of Administration: Segments include intravenous (IV), intramuscular, and oral routes. Notably, the oral administration segment currently holds the largest market share due to patient preference for self-administration.
4. Mechanism of Action: This includes immune checkpoint inhibitors, tumor antigen targeted therapy, cell signaling modulators, and immune modulators.
5. Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies accounting for the largest share.
6. End User: The primary end users include hospitals and clinics, cancer research centers, and other entities.
7. Geographical Regions: The market is analyzed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America, with North America currently holding the largest share.

Challenges

Despite the promising growth, the market faces significant challenges. The high costs associated with cancer immunotherapy, stringent regulatory guidelines, and tumor heterogeneity—which can complicate treatment efficacy—pose substantial barriers. Additionally, immune-related adverse events can hinder widespread adoption.

Key Players in the Industry

The competitive landscape features numerous established and emerging players actively engaging in research and development to enhance clinical pipelines for cancer therapies. Key players include AstraZeneca, Amgen, AbbVie, Bristol-Myers Squibb, and Pfizer, among others. These companies are involved in strategic initiatives such as partnerships and collaborations to advance their therapeutic offerings.

Recent Developments

Recent advancements in the field have seen significant investments in research to enhance cancer immunotherapy. For instance, collaborations like that between The University of Pennsylvania and the Parker Institute for Cancer Immunotherapy, which renewed their alliance with a USD 125 million investment, highlight ongoing efforts to push the boundaries of cancer treatment.

Conclusion

The cancer immunotherapy market is poised for significant growth, driven by increasing cancer incidence and the demand for more effective, targeted therapies. While challenges remain, ongoing research and developments promise to enhance the effectiveness and accessibility of immunotherapy treatments, making this an exciting area of focus within the biopharmaceutical industry.

Thank you for reading Roots Analysis report. Kindly get in touch with Roots’ team to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.